Focused On-demand Library for E3 ubiquitin-protein ligase RNF25

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96BH1

UPID:

RNF25_HUMAN

Alternative names:

RING finger protein 25; RING finger protein AO7

Alternative UPACC:

Q96BH1; A8K0D6; Q53HQ5; Q9H874

Background:

E3 ubiquitin-protein ligase RNF25, also known as RING finger protein 25, plays a pivotal role in the RNF14-RNF25 translation quality control pathway. This pathway activates when a ribosome stalls during translation, leading to the ubiquitination and degradation of translation factors on stalled ribosomes. RNF25 specifically catalyzes the ubiquitination of RPS27A, triggering RNF14 activation, and targets other ribosomal proteins for ubiquitination. Beyond its role in stalled ribosome response, RNF25 is involved in the ubiquitination of NKD2 and may enhance NF-kappa-B mediated transcription through RELA/p65 interaction.

Therapeutic significance:

Understanding the role of E3 ubiquitin-protein ligase RNF25 could open doors to potential therapeutic strategies.